Abbott has integrated its Precision Oncology tests into Flatiron Health’s OncoEMR, enabling more than 4,700 community oncology providers across 1,600+ cancer care centers to order assays like Oncotype DX and view results without leaving the EMR. The move aims to cut workflow friction from test ordering through result delivery, potentially speeding treatment decisions.

Why It Matters To Oncology

• Embedding precision oncology ordering/results in the EMR can reduce administrative handoffs that delay biomarker-informed therapy selection.

• Community settings deliver most cancer care; tighter workflow integration may increase real-world test utilization and adherence to evidence-based pathways.

• A single interface for multiple assays (Oncotype DX Breast Recurrence Score, OncoExTra, Oncodetect, Riskguard) supports more consistent documentation and longitudinal follow-up.

The Financials

• Financial terms were not disclosed.

• Abbott gains broader distribution and “in-workflow” access across Flatiron’s North America footprint (1,600+ centers; 4,700+ providers), a lever for volume growth in decentralized oncology.

• Flatiron adds another major diagnostics partner, extending OncoEMR’s role as a transaction layer for testing and results delivery.

What They're Saying

• Abbott’s Brian Baranick: the integration “removes a key barrier” to accessing the portfolio at the point of care, helping “accelerate treatment decisions” and enabling more personalized care.

• Flatiron’s Quincy Weatherspoon: it’s “reducing friction in the workflow” and helping providers move faster “from test ordering to treatment decisions,” enabling more connected, data-driven point-of-care care.

What's Next

• Watch for adoption metrics: ordering rates, turnaround times, and whether in-EMR status updates reduce incomplete orders and follow-up gaps.

• Expect competitive pressure as other diagnostics companies pursue similar OncoEMR integrations (Natera announced an oncology portfolio integration in November).

• Drug discovery angle: broader, more standardized test capture in community EMRs could expand real-world datasets for biomarker-outcome correlations and trial feasibility signals.